

Mickael Hiligsmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9228285/publications.pdf>

Version: 2024-02-01

203
papers

4,907
citations

87888

38
h-index

133252

59
g-index

211
all docs

211
docs citations

211
times ranked

5920
citing authors

#	ARTICLE	IF	CITATIONS
1	Rationale and Plan for Vitamin D Food Fortification: A Review and Guidance Paper. <i>Frontiers in Endocrinology</i> , 2018, 9, 373.	3.5	249
2	Health economics in the field of osteoarthritis: An Expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 303-313.	3.4	239
3	Using Bestâ€“Worst Scaling to Investigate Preferences in Health Care. <i>Pharmacoeconomics</i> , 2016, 34, 1195-1209.	3.3	164
4	How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3). <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 689-704.	1.4	134
5	A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 268-279.	2.4	130
6	International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. <i>Osteoporosis International</i> , 2017, 28, 767-774.	3.1	113
7	Effectiveness and cost-effectiveness of a nurse-delivered intervention to improve adherence to treatment for HIV: a pragmatic, multicentre, open-label, randomised clinical trial. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 595-604.	9.1	90
8	Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. <i>Patient Preference and Adherence</i> , 2013, 7, 133.	1.8	87
9	A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis. <i>Pharmacoeconomics</i> , 2015, 33, 205-224.	3.3	84
10	Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications. <i>Calcified Tissue International</i> , 2010, 86, 202-210.	3.1	77
11	Utility Values Associated with Osteoporotic Fracture: A Systematic Review of the Literature. <i>Calcified Tissue International</i> , 2008, 82, 288-292.	3.1	75
12	Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. <i>Osteoporosis International</i> , 2013, 24, 2907-2918.	3.1	75
13	Management of osteoporosis of the oldest old. <i>Osteoporosis International</i> , 2014, 25, 2507-2529.	3.1	71
14	Exploring consensus on how to measure smoking cessation. A Delphi study. <i>BMC Public Health</i> , 2017, 17, 890.	2.9	70
15	Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis. <i>Value in Health</i> , 2009, 12, 687-696.	0.3	69
16	Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). <i>Osteoporosis International</i> , 2019, 30, 2155-2165.	3.1	69
17	Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an expertsâ€™ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. <i>Osteoporosis International</i> , 2019, 30, 45-57.	3.1	67
18	Newborn screening for SMA in Southern Belgium. <i>Neuromuscular Disorders</i> , 2019, 29, 343-349.	0.6	65

#	ARTICLE	IF	CITATIONS
19	An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis. <i>Pharmacoeconomics</i> , 2021, 39, 181-209.	3.3	63
20	A reappraisal of generic bisphosphonates in osteoporosis. <i>Osteoporosis International</i> , 2012, 23, 213-221.	3.1	62
21	Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium. <i>Pharmacoeconomics</i> , 2011, 29, 895-911.	3.3	61
22	Patients' Preferences for Outcome, Process and Cost Attributes in Cancer Treatment: A Systematic Review of Discrete Choice Experiments. <i>Patient</i> , 2017, 10, 553-565.	2.7	57
23	The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. <i>Health Policy</i> , 2010, 96, 170-177.	3.0	56
24	Partial adherence: a new perspective on health economic assessment in osteoporosis. <i>Osteoporosis International</i> , 2011, 22, 2565-2573.	3.1	55
25	244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofddorp, The Netherlands. <i>Neuromuscular Disorders</i> , 2020, 30, 93-103.	0.6	55
26	Cost-Effectiveness of Osteoporosis Screening Followed by Treatment: The Impact of Medication Adherence. <i>Value in Health</i> , 2010, 13, 394-401.	0.3	54
27	Risk of bias in model-based economic evaluations: the ECOBIAS checklist. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 513-523.	1.4	54
28	Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 47.	2.7	54
29	A FRAX® model for the assessment of fracture probability in Belgium. <i>Osteoporosis International</i> , 2011, 22, 453-461.	3.1	53
30	The Clinical and Economic Burden of Poor Adherence and Persistence with Osteoporosis Medications in Ireland. <i>Value in Health</i> , 2012, 15, 604-612.	0.3	52
31	The impact of fracture liaison services on subsequent fractures and mortality: a systematic literature review and meta-analysis. <i>Osteoporosis International</i> , 2021, 32, 1517-1530.	3.1	51
32	Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review. <i>Osteoporosis International</i> , 2020, 31, 1645-1669.	3.1	49
33	The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 159-166.	1.4	48
34	Cost-effectiveness of interventions for treating anxiety disorders: A systematic review. <i>Journal of Affective Disorders</i> , 2017, 210, 1-13.	4.1	48
35	Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2019, 31, 905-915.	2.9	47
36	Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment. <i>Arthritis Research and Therapy</i> , 2014, 16, R36.	3.5	44

#	ARTICLE	IF	CITATIONS
37	Risk of bias in trial-based economic evaluations: Identification of sources and bias-reducing strategies. <i>Psychology and Health</i> , 2015, 30, 52-71.	2.2	41
38	Cost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis. <i>European Journal of Public Health</i> , 2015, 25, 20-25.	0.3	41
39	Health Technology Assessment in Osteoporosis. <i>Calcified Tissue International</i> , 2013, 93, 1-14.	3.1	39
40	Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. <i>Bone</i> , 2010, 47, 34-40.	2.9	37
41	Trends in hip fracture incidence and in the prescription of antiosteoporosis medications during the same time period in Belgium (2000â€“2007). <i>Arthritis Care and Research</i> , 2012, 64, 744-750.	3.4	37
42	Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy. <i>The Cochrane Library</i> , 2017, 2, CD008312.	2.8	37
43	Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women. <i>Bone</i> , 2008, 43, 991-994.	2.9	36
44	A Review of Patient Preferences for Osteoporosis Drug Treatment. <i>Current Rheumatology Reports</i> , 2015, 17, 61.	4.7	35
45	Burden of disease of type 2 diabetes mellitus: cost of illness and quality of life estimated using the Maastricht Study. <i>Diabetic Medicine</i> , 2020, 37, 1759-1765.	2.3	35
46	Cost-effectiveness of personalized supplementation with vitamin D-rich dairy products in the prevention of osteoporotic fractures. <i>Osteoporosis International</i> , 2016, 27, 301-308.	3.1	33
47	Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 126-132.	0.9	33
48	Burden of disease study of overweight and obesity; the societal impact in terms of cost-of-illness and health-related quality of life. <i>BMC Public Health</i> , 2022, 22, 46.	2.9	33
49	Management of patients at very high risk of osteoporotic fractures through sequential treatments. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 695-714.	2.9	33
50	Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. <i>International Journal of Clinical Practice</i> , 2010, 64, 756-762.	1.7	32
51	Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium. <i>Scientific Reports</i> , 2021, 11, 19922.	3.3	32
52	Identification and Prioritization of Important Attributes of Disease-Modifying Drugs in Decision Making among Patients with Multiple Sclerosis: A Nominal Group Technique and Best-Worst Scaling. <i>PLoS ONE</i> , 2016, 11, e0164862.	2.5	30
53	Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 184-196.	3.4	30
54	A reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 271-282.	3.4	29

#	ARTICLE	IF	CITATIONS
55	Perioperative lipid-enriched enteral nutrition versus standard care in patients undergoing elective colorectal surgery (SANICS II): a multicentre, double-blind, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 242-251.	8.1	28
56	Model-based economic evaluations in smoking cessation and their transferability to new contexts: a systematic review. <i>Addiction</i> , 2017, 112, 946-967.	3.3	27
57	Economic Burden of Multiple Sclerosis in Low- and Middle-income Countries: A Systematic Review. <i>Pharmacoeconomics</i> , 2021, 39, 789-807.	3.3	27
58	Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment. <i>Rheumatology</i> , 2017, 56, 1167-1176.	1.9	26
59	Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. <i>Osteoporosis International</i> , 2010, 21, 157-165.	3.1	25
60	The clinical and economical impact of postoperative ileus in patients undergoing colorectal surgery. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13862.	3.0	25
61	Public health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fractures. <i>Archives of Public Health</i> , 2015, 73, 48.	2.4	24
62	Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. <i>Bone</i> , 2010, 46, 440-446.	2.9	23
63	Understanding the stakeholders' intention to use economic decision-support tools: A cross-sectional study with the tobacco return on investment tool. <i>Health Policy</i> , 2016, 120, 46-54.	3.0	23
64	Patients' preferences for osteoarthritis treatment: the value of stated-preference studies. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 1-3.	2.9	23
65	The use of routinely collected patient-reported outcome measures in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 357-366.	3.4	22
66	Health-Related Quality of Life of Patients with HIV/AIDS in Bogotá, Colombia. <i>Value in Health Regional Issues</i> , 2016, 11, 68-72.	1.2	21
67	Comparing Analytic Hierarchy Process and Discrete-Choice Experiment to Elicit Patient Preferences for Treatment Characteristics in Age-Related Macular Degeneration. <i>Value in Health</i> , 2017, 20, 1166-1173.	0.3	21
68	Comparison of preferences of healthcare professionals and MS patients for attributes of disease-modifying drugs: A best-worst scaling. <i>Health Expectations</i> , 2018, 21, 171-180.	2.6	20
69	Development and application of an economic model (EQUIPTMOD) to assess the impact of smoking cessation. <i>Addiction</i> , 2018, 113, 7-18.	3.3	20
70	Preferences of people with Type 2 diabetes for diabetes care: a discrete choice experiment. <i>Diabetic Medicine</i> , 2020, 37, 1807-1815.	2.3	20
71	Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening. <i>Developmental Medicine and Child Neurology</i> , 2023, 65, 67-77.	2.1	20
72	Similarities and differences between stakeholders' opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey. <i>Health Research Policy and Systems</i> , 2016, 14, 38.	2.8	19

#	ARTICLE	IF	CITATIONS
73	How Well Can Analytic Hierarchy Process be Used to Elicit Individual Preferences? Insights from a Survey in Patients Suffering from Age-Related Macular Degeneration. <i>Patient</i> , 2016, 9, 481-492.	2.7	19
74	Public health impact and economic evaluation of vitamin D-fortified dairy products for fracture prevention in France. <i>Osteoporosis International</i> , 2017, 28, 833-840.	3.1	19
75	Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 19-28.	1.4	18
76	Using multi-criteria decision analysis to appraise orphan drugs: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 135-146.	1.4	18
77	Patients' preferences for the treatment of anxiety and depressive disorders: a systematic review of discrete choice experiments. <i>Journal of Medical Economics</i> , 2020, 23, 546-556.	2.1	18
78	Systematic review and overview of health economic evaluation models in obesity prevention and therapy. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 561-570.	1.4	17
79	Economic evaluations of interventions to manage hyperphosphataemia in adult haemodialysis patients: A systematic review. <i>Nephrology</i> , 2016, 21, 178-187.	1.6	17
80	The application of health technology assessment in osteoporosis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 895-910.	4.7	16
81	Using qualitative research to facilitate the interpretation of quantitative results from a discrete choice experiment: insights from a survey in elderly ophthalmologic patients. <i>Patient Preference and Adherence</i> , 2016, 10, 993.	1.8	16
82	A discrete-choice experiment to assess treatment modality preferences of patients with depression. <i>Journal of Medical Economics</i> , 2019, 22, 178-186.	2.1	16
83	The importance of understanding patient and physician preferences for psoriasis treatment characteristics: a systematic review of discrete-choice experiments. <i>Current Medical Research and Opinion</i> , 2020, 36, 1257-1275.	1.9	16
84	Vaccine preferences driving vaccine-decision making of different target groups: a systematic review of choice-based experiments. <i>BMC Infectious Diseases</i> , 2021, 21, 879.	2.9	16
85	Focus Groups in Elderly Ophthalmologic Patients: Setting the Stage for Quantitative Preference Elicitation. <i>Patient</i> , 2016, 9, 47-57.	2.7	15
86	A scoping review of the public health impact of vitamin D-fortified dairy products for fracture prevention. <i>Archives of Osteoporosis</i> , 2017, 12, 57.	2.4	15
87	Comparison of statistical analysis methods for object case best-worst scaling. <i>Journal of Medical Economics</i> , 2019, 22, 509-515.	2.1	15
88	Best-worst scaling identified adequate statistical methods and literature search as the most important items of AMSTAR2 (A measurement tool to assess systematic reviews). <i>Journal of Clinical Epidemiology</i> , 2020, 128, 74-82.	5.0	15
89	Hip protectors are cost-effective in the prevention of hip fractures in patients with high fracture risk. <i>Osteoporosis International</i> , 2020, 31, 1217-1229.	3.1	15
90	Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e40.	0.5	15

#	ARTICLE	IF	CITATIONS
91	Eliciting patients' preferences for epilepsy diagnostics: A discrete choice experiment. <i>Epilepsy and Behavior</i> , 2014, 31, 102-109.	1.7	14
92	A discrete-choice experiment to elicit preferences of patients with epilepsy for self-management programs. <i>Epilepsy and Behavior</i> , 2018, 79, 58-67.	1.7	14
93	Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. <i>Osteoporosis International</i> , 2019, 30, 649-658.	3.1	14
94	Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 394-400.	3.4	14
95	The effects of stimulation of the autonomic nervous system via perioperative nutrition on postoperative ileus and anastomotic leakage following colorectal surgery (SANICS II trial): a study protocol for a double-blind randomized controlled trial. <i>Trials</i> , 2015, 16, 20.	1.6	13
96	A societal cost-of-illness study of hemodialysis in Lebanon. <i>Journal of Medical Economics</i> , 2016, 19, 1157-1166.	2.1	13
97	The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogotá. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 303-310.	1.4	13
98	Exploring Women Healthcare Leaders' Perceptions on Barriers to Leadership in Greek Context. <i>Frontiers in Public Health</i> , 2019, 7, 68.	2.7	13
99	Outcome Priorities for Older Persons With Sarcopenia. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 267-271.e2.	2.5	13
100	Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy. <i>The Cochrane Library</i> , 2020, 2020, CD008312.	2.8	13
101	Identifying Unmet Care Needs and Important Treatment Attributes in the Management of Hidradenitis Suppurativa: A Qualitative Interview Study. <i>Patient</i> , 2022, 15, 207-218.	2.7	13
102	The development of a personalized patient education tool for decision making for postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , 2016, 27, 2489-2496.	3.1	12
103	Most important barriers and facilitators of HTA usage in decision-making in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 297-304.	1.4	12
104	Parent, provider and vaccinee preferences for HPV vaccination: A systematic review of discrete choice experiments. <i>Vaccine</i> , 2020, 38, 7226-7238.	3.8	12
105	Health Care Use and Costs in Individuals With Diabetes With and Without Comorbid Depression in Germany: Results of the Cross-sectional DiaDec Study. <i>Diabetes Care</i> , 2021, 44, 407-415.	8.6	12
106	Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis. <i>Journal of Medical Economics</i> , 2009, 12, 356-360.	2.1	11
107	MOST IMPORTANT BARRIERS AND FACILITATORS REGARDING THE USE OF HEALTH TECHNOLOGY ASSESSMENT. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 183-191.	0.5	11
108	A best-worst scaling in Colombian patients to rank the characteristics of HIV/AIDS treatment. <i>Journal of Medical Economics</i> , 2018, 21, 468-473.	2.1	11

#	ARTICLE	IF	CITATIONS
109	Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 269-279.	1.4	11
110	A discrete choice experiment to assess patients' preferences for HIV treatment in the urban population in Colombia. <i>Journal of Medical Economics</i> , 2020, 23, 812-818.	2.1	11
111	Health-related quality of life of patients with a recent fracture attending a fracture liaison service: a 3-year follow-up study. <i>Osteoporosis International</i> , 2022, 33, 577-588.	3.1	11
112	Economic evaluation guidelines in low- and middle-income countries: a systematic review. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, e1.	0.5	11
113	An Economic Evaluation of Quantitative Ultrasonometry as Pre-Screening Test for the Identification of Patients with Osteoporosis. <i>Disease Management and Health Outcomes</i> , 2008, 16, 429-438.	0.4	10
114	Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis. <i>Osteoporosis International</i> , 2013, 24, 2291-2300.	3.1	10
115	Best-worst scaling to assess the most important barriers and facilitators for the use of health technology assessment in Austria. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 223-232.	1.4	10
116	Potential clinical and economic impact of nonadherence with osteoporosis medications. <i>Calcified Tissue International</i> , 2010, 86, 202-10.	3.1	10
117	Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 359-366.	1.4	9
118	Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 807-815.	2.8	9
119	Analysis of a Small Group of Stakeholders Regarding Advancing Health Technology Assessment in India. <i>Value in Health Regional Issues</i> , 2014, 3, 167-171.	1.2	9
120	Estimates of costs for modelling return on investment from smoking cessation interventions. <i>Addiction</i> , 2018, 113, 32-41.	3.3	9
121	EARLY DIALOGUE IN EUROPE: PERSPECTIVES ON VALUE, CHALLENGES, AND CONTINUING EVOLUTION. <i>International Journal of Technology Assessment in Health Care</i> , 2018, 34, 514-518.	0.5	9
122	A discrete-choice experiment to assess treatment modality preferences of patients with anxiety disorder. <i>Journal of Medical Economics</i> , 2019, 22, 169-177.	2.1	9
123	Using statutory health insurance data to evaluate non-response in a cross-sectional study on depression among patients with diabetes in Germany. <i>International Journal of Epidemiology</i> , 2020, 49, 629-637.	1.9	9
124	Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women. <i>Osteoporosis International</i> , 2021, 32, 133-144.	3.1	9
125	Adherence to Web-Based Self-Assessments in Long-Term Direct-to-Patient Research: Two-Year Study of Multiple Sclerosis Patients. <i>Journal of Medical Internet Research</i> , 2017, 19, e249.	4.3	9
126	A systematic review of economic evaluations of screening programmes for cardiometabolic diseases. <i>European Journal of Public Health</i> , 2016, 27, ckw237.	0.3	8

#	ARTICLE	IF	CITATIONS
127	Effect of stage-based education provided by dedicated dietitians on hyperphosphataemic haemodialysis patients: results from the Nutrition Education for Management of Osteodystrophy randomised controlled trial. <i>Journal of Human Nutrition and Dietetics</i> , 2017, 30, 554-562.	2.5	8
128	Quality of life and costs of patients prior to colorectal surgery. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 193-198.	1.4	8
129	Understanding patients' preferences for osteoporosis treatment: the impact of patients' characteristics on subgroups and latent classes. <i>Osteoporosis International</i> , 2020, 31, 85-96.	3.1	8
130	Effect of direct oral feeding following minimally invasive esophagectomy on costs and quality of life. <i>Journal of Medical Economics</i> , 2021, 24, 54-60.	2.1	8
131	Improvement of osteoporosis Care Organized by Nurses: ICON study - Protocol of a quasi-experimental study to assess the (cost)-effectiveness of combining a decision aid with motivational interviewing for improving medication persistence in patients with a recent fracture being treated at the fracture liaison service. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 913.	1.9	8
132	EVALUATION OF THE HTA CORE MODEL FOR NATIONAL HEALTH TECHNOLOGY ASSESSMENT REPORTS: COMPARATIVE STUDY AND EXPERIENCES FROM EUROPEAN COUNTRIES. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 644-653.	0.5	7
133	Cost-effectiveness of dedicated dietitians for hyperphosphatemia management among hemodialysis patients in Lebanon: results from the Nutrition Education for Management of Osteodystrophy trial. <i>Journal of Medical Economics</i> , 2017, 20, 1024-1038.	2.1	7
134	Assessment of cost-effective changes to the current and potential provision of smoking cessation services: an analysis based on the EQUIPTMOD. <i>Addiction</i> , 2018, 113, 96-105.	3.3	7
135	A discrete-choice experiment to assess patients' preferences for osteoarthritis treatment: An ESCO working group. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 859-866.	3.4	7
136	Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model. <i>Medical Decision Making</i> , 2020, 40, 1003-1019.	2.4	7
137	A discrete choice experiment to assess patients' preferences for HIV treatment in the rural population in Colombia. <i>Journal of Medical Economics</i> , 2020, 23, 803-811.	2.1	7
138	Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy. <i>Osteoporosis International</i> , 2021, 32, 595-606.	3.1	7
139	Patient preferences to value health outcomes in rheumatology clinical trials: Report from the OMERACT special interest group. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 919-924.	3.4	7
140	Early intervention for subthreshold panic disorder in the Netherlands: A model-based economic evaluation from a societal perspective. <i>PLoS ONE</i> , 2018, 13, e0193338.	2.5	7
141	Economic evaluation of a JAK inhibitor compared to a monoclonal antibody for treatment of moderate-to-severe atopic dermatitis from a UK perspective. <i>Journal of Medical Economics</i> , 2022, 25, 491-502.	2.1	7
142	Relevance of barriers and facilitators in the use of health technology assessment in Colombia. <i>Journal of Medical Economics</i> , 2018, 21, 510-517.	2.1	6
143	Health-related quality of life and cost-effectiveness analysis of gum chewing in patients undergoing colorectal surgery: results of a randomized controlled trial. <i>Acta Chirurgica Belgica</i> , 2018, 118, 299-306.	0.4	6
144	The projected public health and economic impact of vitamin D fortified dairy products for fracture prevention in France. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 191-195.	1.4	6

#	ARTICLE	IF	CITATIONS
145	Economic evaluation of prolonged and enhanced ECG Holter monitoring in acute ischemic stroke patients. <i>Current Medical Research and Opinion</i> , 2019, 35, 1859-1866.	1.9	6
146	Patient's Engagement in the Identification of Critical Outcomes in Sarcopenia. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 284-286.	2.5	6
147	Patient decision aid based on multi-criteria decision analysis for disease-modifying drugs for multiple sclerosis: prototype development. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 123.	3.0	6
148	Effective communication regarding risk of fracture for individuals at risk of fragility fracture: a scoping review. <i>Osteoporosis International</i> , 2022, 33, 13-26.	3.1	6
149	Economic evaluation of deep brain stimulation compared with vagus nerve stimulation and usual care for patients with refractory epilepsy: A lifetime decision analytic model. <i>Epilepsia</i> , 2022, 63, 641-651.	5.1	6
150	OPTIMIZING USABILITY OF AN ECONOMIC DECISION SUPPORT TOOL: PROTOTYPE OF THE EQUIPT TOOL. <i>International Journal of Technology Assessment in Health Care</i> , 2018, 34, 68-77.	0.5	5
151	Patients' preferences in periodontal disease treatment elicited alongside an IQWiG benefit assessment: a feasibility study. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2437-2447.	1.8	5
152	Event simulation and external validation applied in published health economic models for obesity: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 529-541.	1.4	5
153	Willingness to pay for primary health care at public facilities in the Western Cape Province, Cape Town, South Africa. <i>Journal of Medical Economics</i> , 2021, 24, 162-172.	2.1	5
154	Replication of Published Health Economic Obesity Models: Assessment of Facilitators, Hurdles and Reproduction Success. <i>Pharmacoeconomics</i> , 2021, 39, 433-446.	3.3	5
155	Cost-effectiveness analyses comparing cemented, cementless, hybrid and reverse hybrid fixation in total hip arthroplasty: a systematic overview and critical appraisal of the current evidence. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 579-593.	1.4	5
156	Potential cost-effectiveness for using patient decision aids to guide osteoporosis treatment. <i>Osteoporosis International</i> , 2016, 27, 2697-2707.	3.1	4
157	A Cost-of-Illness Study of Patients with HIV/AIDS in Bogotá, Colombia. <i>Value in Health Regional Issues</i> , 2017, 14, 103-107.	1.2	4
158	Chinese patients' preference for pharmaceutical treatments of osteoporosis: a discrete choice experiment. <i>Archives of Osteoporosis</i> , 2019, 14, 85.	2.4	4
159	Evidence-informed vaccine decision making: The introduction of Human Papilloma Virus (HPV) vaccination in the Netherlands. <i>Health Policy</i> , 2019, 123, 260-266.	3.0	4
160	Pharmacoeconomic Analyses and Modeling. , 2019, , 261-275.		4
161	Early health economic modelling for a treatment candidate in hidradenitis suppurativa. <i>Journal of Medical Economics</i> , 2020, 23, 1516-1524.	2.1	4
162	The Economic and societal burden of multiple sclerosis on lebanese society: a cost-of-illness and quality of life study protocol. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 869-876.	1.4	4

#	ARTICLE	IF	CITATIONS
163	Comment on: Patientsâ€™ preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment: reply. <i>Rheumatology</i> , 2018, 57, 584-585.	1.9	3
164	Understanding patientsâ€™ preferences for HIV treatment among rural and urban Colombian patients. <i>Journal of Medical Economics</i> , 2020, 23, 801-802.	2.1	3
165	A Digital Innovation for the Personalized Management of Adherence: Analysis of Strengths, Weaknesses, Opportunities, and Threats. <i>Frontiers in Medical Technology</i> , 2020, 2, 604183.	2.5	3
166	Identification and expert panel rating of key structural approaches applied in health economic obesity models. <i>Health Policy and Technology</i> , 2020, 9, 314-322.	2.5	3
167	The Relative Importance of Education and Criminal Justice Costs and Benefits in Economic Evaluations: A Bestâ€“Worst Scaling Experiment. <i>Pharmacoeconomics</i> , 2021, 39, 99-108.	3.3	3
168	Expertsâ€™ preferences for sarcopenia outcomes: a discrete-choice experiment from a working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) in collaboration with the European Union of Geriatric Medicine Society (EUGMS). <i>Aging Clinical and Experimental Research</i> , 2021, 33, 1079-1083.	2.9	3
169	Most Important Factors for Deciding Rehabilitation Provision for Severe Stroke Survivors Post Hospital Discharge: A Study Protocol for a Bestâ€“Worst Scaling Experiment. <i>Methods and Protocols</i> , 2021, 4, 27.	2.0	3
170	Identification and Prioritization of Attributes for a Discrete Choice Experiment Using the Nominal Group Technique: Patientsâ€™ Choice of Public Health Facilities in Cape Town, South Africa. <i>Value in Health Regional Issues</i> , 2022, 27, 90-98.	1.2	3
171	Optimising Access Surgery in Senior Haemodialysis Patients (OASIS): study protocol for a multicentre randomised controlled trial. <i>BMJ Open</i> , 2022, 12, e053108.	1.9	3
172	Evidence-based recommendations for economic evaluations in spine surgery: study protocol for a Delphi consensus. <i>BMJ Open</i> , 2021, 11, e052988.	1.9	3
173	Improving the reporting of economic evaluation in osteoporosis: the value of CHEERS 2022 statement. <i>Osteoporosis International</i> , 2022, , 1.	3.1	3
174	PMS39 MOST EFFECTIVE ADHERENCE-ENHANCING INTERVENTIONS FOR OSTEOPOROSIS MEDICATIONS. <i>Value in Health</i> , 2011, 14, A130.	0.3	2
175	Identification and Prioritization of the Economic Impacts of Vaccines. <i>BioMed Research International</i> , 2016, 2016, 1-8.	1.9	2
176	Promoting the consumption of dairy products for fracture prevention: A good value for money?. <i>Joint Bone Spine</i> , 2018, 85, 403-404.	1.6	2
177	Applying a best-worst scaling methodology to prioritise important attributes of counselling from community pharmacy usersâ€™ perspective, Saudi Arabia. <i>Journal of Pharmaceutical Health Services Research</i> , 2018, 9, 153-159.	0.6	2
178	Understanding perceived availability and importance of tobacco control interventions to inform European adoption of a UK economic model: a cross-sectional study. <i>BMC Health Services Research</i> , 2018, 18, 115.	2.2	2
179	A discrete choice experiment to investigate patient preferences for HIV testing programs in Bogotá, Colombia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 195-201.	1.4	2
180	The Value of a Patient-Level Modeling Approach and Need for Better Reporting in Economic Evaluations of Osteoporosis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 334-335.	0.9	2

#	ARTICLE	IF	CITATIONS
181	The most important facilitators and barriers to the use of Health Technology Assessment in Canada: a bestâ€“worst scaling approach. <i>Journal of Medical Economics</i> , 2021, 24, 846-856.	2.1	2
182	Enhancing Public Participation in Public Health Offerings: Patient Preferences for Facilities in the Western Cape Province Using a Discrete Choice Experiment. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 590.	2.6	2
183	Patientsâ€™ and Psychologistsâ€™ Preferences for Feedback Reports on Expected Mental Health Treatment Outcomes: A Discrete-Choice Experiment. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2022, 49, 707-721.	2.1	2
184	A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service. <i>Journal of Medical Economics</i> , 2022, 25, 829-839.	2.1	2
185	PMS40 COST-EFFECTIVENESS OF DENOSUMAB COMPARED WITH GENERIC ALENDRONATE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROTIC WOMEN. <i>Value in Health</i> , 2010, 13, A309-A310.	0.3	1
186	The need for (cost)-effective interventions to enhance adherence with osteoporosis medications. <i>Current Medical Research and Opinion</i> , 2014, 30, 297-299.	1.9	1
187	An economic evaluation of perioperative enteral nutrition in patients undergoing colorectal surgery (SANICS II study). <i>Journal of Medical Economics</i> , 2019, 22, 238-244.	2.1	1
188	Evaluating Health Related Quality of Life in Older People at Risk of Osteoporotic Fracture: A Head-to-Head Comparison of the EQ-5D-5L and AQoL-6D. <i>Social Indicators Research</i> , 2022, 160, 809-824.	2.7	1
189	Effective Risk Communication and Improving Adherence. , 2021, , 115-143.		1
190	Using health-economic evidence to support policy-level decision-making in Singaporeâ€™s sensitivity analysis that provides further confidence in fracture probability-based cost-effective intervention thresholds. <i>Osteoporosis International</i> , 2021, 32, 787-789.	3.1	1
191	Mogamulizumab for Previously Treated Mycosis Fungoides and SÃ©zary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2022, 40, 509-518.	3.3	1
192	The development process of economic evaluation guidelines in low- and middle-income countries: a systematic review. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, e35.	0.5	1
193	Global article collection: essential reads from around the world. <i>Journal of Medical Economics</i> , 2022, 25, 864-869.	2.1	1
194	Value of information analysis of an early intervention for subthreshold panic disorder: Healthcare versus societal perspective. <i>PLoS ONE</i> , 2018, 13, e0205876.	2.5	0
195	No consensus on cementless fixation currently being the most costâ€“effective mode of implant fixation in younger total hip arthroplasty patients. <i>International Journal of Clinical Practice</i> , 2021, 75, e14587.	1.7	0
196	Patientsâ€™ preferences for quality-of-life aspects in sarcopenia: a bestâ€“worst scaling study. <i>European Geriatric Medicine</i> , 2021, , 1.	2.8	0
197	Assessment of Quality of Life 8-Dimension (AQoL-8D): translation, validation, and application in two Dutch trials in patients with epilepsy and schizophrenia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 795-803.	1.4	0
198	The economic burden of the postoperative management in surgically treated trauma patients with peri- and/or intra-articular fractures of the lower extremities: A prospective multicenter cohort study. <i>Injury</i> , 2021, , .	1.7	0

#	ARTICLE	IF	CITATIONS
199	Patient preferences for lifestyle behaviours in osteoporotic fracture prevention: a cross-European discrete choice experiment. <i>Osteoporosis International</i> , 2022, , 1.	3.1	0
200	DISCRETE CHOICE EXPERIMENT TO INVESTIGATE PREFERENCES FOR INCENTIVES TO PROMOTE ANTIMICROBIAL RESEARCH & DEVELOPMENT. <i>Journal of Global Antimicrobial Resistance</i> , 2022, , .	2.2	0
201	A discrete choice experiment investigating HIV testing preferences in South Africa. <i>Journal of Medical Economics</i> , 2022, 25, 481-490.	2.1	0
202	A Qualitative Study to Assess US Patient Preferences between new Transdermal System and Injectable Anabolic Therapies for Osteoporosis Treatment. <i>Archives of Osteoporosis</i> , 2022, 17, 57.	2.4	0
203	Does the Structure Matter? An External Validation and Health Economic Results Comparison of Event Simulation Approaches in Severe Obesity. <i>Pharmacoeconomics</i> , 0, , .	3.3	0